MGMT promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas

C. Mircea S. Tesileanu; Thierry Gorlia; EORTC Brain Tumor Group; the CATNON investigators; Vassilis Golfinopoulos; Pim J. French; Martin J. Van Den Bent

doi:10.1093/neuonc/noac014

MGMT promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas

C. Mircea S. Tesileanu
, Thierry Gorlia
, EORTC Brain Tumor Group
, the CATNON investigators
, Vassilis Golfinopoulos
, Pim J. French
, Martin J. Van Den Bent^*

^*Corresponding author for this work

Neurology

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

13 Citations (Scopus)

32 Downloads (Pure)

Original language	English
Pages (from-to)	665-667
Number of pages	3
Journal	Neuro-Oncology
Volume	24
Issue number	4
Early online date	31 Jan 2022
DOIs	https://doi.org/10.1093/neuonc/noac014
Publication status	Published - 1 Apr 2022

Bibliographical note

The CATNON study was funded by Merck, Sharp and Dohme (MSD) formerly Schering-Plough by an educational grant and by the provision of temozolomide. The clinical study was also supported by the NRG (grants U10CA180868 and U10CA180822), Cancer Research UK grant CRUK/07/028, and Cancer Australia (project grants 1026842 and 1078655). The molecular study was funded by grant GN-000577 from The Brain Tumour Charity, grant 10685 from the Dutch Cancer Society, and financial support from the Vereniging Heino “Strijd van Salland”

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/neuonc/noac014

noac014Final published version, 172 KB

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972205/

Cite this

@article{24a7498b6a064c419e900480aae0aee9,

title = "MGMT promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas",

author = "Tesileanu, \{C. Mircea S.\} and Thierry Gorlia and \{EORTC Brain Tumor Group\} and \{the CATNON investigators\} and Vassilis Golfinopoulos and French, \{Pim J.\} and \{Van Den Bent\}, \{Martin J.\}",

note = "The CATNON study was funded by Merck, Sharp and Dohme (MSD) formerly Schering-Plough by an educational grant and by the provision of temozolomide. The clinical study was also supported by the NRG (grants U10CA180868 and U10CA180822), Cancer Research UK grant CRUK/07/028, and Cancer Australia (project grants 1026842 and 1078655). The molecular study was funded by grant GN-000577 from The Brain Tumour Charity, grant 10685 from the Dutch Cancer Society, and financial support from the Vereniging Heino “Strijd van Salland”",

year = "2022",

month = apr,

day = "1",

doi = "10.1093/neuonc/noac014",

language = "English",

volume = "24",

pages = "665--667",

journal = "Neuro-Oncology",

issn = "1522-8517",

publisher = "Oxford University Press",

number = "4",

}

MGMT promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas. / Tesileanu, C. Mircea S.; Gorlia, Thierry; EORTC Brain Tumor Group et al.
In: Neuro-Oncology, Vol. 24, No. 4, 01.04.2022, p. 665-667.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - MGMT promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas

AU - Tesileanu, C. Mircea S.

AU - Gorlia, Thierry

AU - EORTC Brain Tumor Group

AU - the CATNON investigators

AU - Golfinopoulos, Vassilis

AU - French, Pim J.

AU - Van Den Bent, Martin J.

N1 - The CATNON study was funded by Merck, Sharp and Dohme (MSD) formerly Schering-Plough by an educational grant and by the provision of temozolomide. The clinical study was also supported by the NRG (grants U10CA180868 and U10CA180822), Cancer Research UK grant CRUK/07/028, and Cancer Australia (project grants 1026842 and 1078655). The molecular study was funded by grant GN-000577 from The Brain Tumour Charity, grant 10685 from the Dutch Cancer Society, and financial support from the Vereniging Heino “Strijd van Salland”

PY - 2022/4/1

Y1 - 2022/4/1

UR - https://www.scopus.com/pages/publications/85126811992

U2 - 10.1093/neuonc/noac014

DO - 10.1093/neuonc/noac014

M3 - Comment/Letter to the editor

C2 - 35099533

AN - SCOPUS:85126811992

SN - 1522-8517

VL - 24

SP - 665

EP - 667

JO - Neuro-Oncology

JF - Neuro-Oncology

IS - 4

ER -

MGMT promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas

Bibliographical note

UN SDGs

Access to Document

Other files and links

Cite this